Effect of low intensity vibration (LIV) on aromatase inhibitor- induced musculoskeletal dysfunction in early stage breast cancer survivors
T
Tarah Ballinger, MD
Primary Investigator
Overview
A type of breast cancer medicine called aromatase inhibitors (AI) causes muscle weakness and bone loss in patients. This research is being done to test whether low intensity vibration (LIV) can prevent the loss of muscle and bone strength in patients receiving AIs.
Description
The primary objective of this study is to compare the effect of LIV delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer planned to initiate aromatase inhibitor therapy who do not currently participate in regular exercise, compared to a wait- listed control.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer,1808152332
-
Age: Between 18 Years - 100 Years
-
Gender: Female
Updated on
26 Apr 2024.
Study ID: 1808152332
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
